GLAND IN EQUITY
loading…—
Day range—
52-week range—
Market cap—
P/E · TTM—
As of—
| CUSTOMER | BASIS | EST ₹CR | RANGE | % REV | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| Australia | REV SHARE | 225 | 225–225 | 4.0% | — | FY25 | DISC | 90% |
| “Revenue from the US (` in Million) `30,387 Mn FY 25 30,387 30,375FY 24 US market 54% Share of group revenue contribution Revenue from Europe (` in Million) `10…” AR · +2 DOC | ||||||||
| FY27 | REV SHARE | — | — | 4.0% | R&D | FY27 | DISC | 80% |
| “During Q1 FY27, we spent INR772 million on R&D, representing around 4% of consolidated revenue.” CONCALL DOC | ||||||||
| Office | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “Liabilities assumed: Borrowings (122.97) (11,099.51) Trade Payables (75.05) (6,774.21) Deferred tax liabilities, net (7.99) (720.93) Contingent liability (1.00…” AR · +1 DOC | ||||||||
| China. | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “Mr. Zhang served as general Manager of Amgen China and also worked as Vice President, Oncology for Roche China from 2010 to 2014.” AR · +1 DOC | ||||||||
| Parties | CONTRACT | CT 6 | — | — | — | FY26 | EST | 75% |
| “The details of other contracts or arrangements with the Related Parties at arm’s length basis are set out in the standalone financial statements forming part o…” AR · +2 DOC | ||||||||
| Others | UNSTATED | — | — | — | CAPEX | FY26 | EST | 70% |
| “Significant change in contract liabilities is explained as follows: For the year ended March 31, 2026 For the year ended March 31, 2025 Balance at the beginnin…” AR DOC | ||||||||
| Others | UNSTATED | — | — | — | R&D | FY26 | EST | 70% |
| “Repairs and maintenance: Plant and machinery 488.69 409.63 Buildings 160.87 161.24 Others 50.89 52.84 Rates and taxes 450.23 416.68 Quality control expenses 70…” AR · +1 DOC | ||||||||
| Securities and Exchange Board of India | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “(f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing wit…” AR · +1 DOC | ||||||||
| Authority. | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “from Dr. Jia Ai Zhang to the effect that he is not disqualified in accordance with Section 164(2) of the Companies Act, 2013 and a declaration that he is not d…” AR · +1 DOC | ||||||||
| Financial Year | UNSTATED | — | — | — | — | FY26 | EST | 70% |
| “Details of material contracts or arrangements or transactions at arm’s length basis There were no material contracts or arrangements or transactions made with …” AR · +1 DOC | ||||||||
| Others | UNSTATED | — | — | — | — | FY25 | EST | 70% |
| “Weblink: https:// scores.sebi.gov.in/ scores-home NIL NIL NA NIL NIL NA Employees and workers Yes https://glandphar- ma.com/images/ Whistle_blow- er_policy-ame…” AR DOC | ||||||||
| Australia | UNSTATED | — | — | — | R&D | FY25 | EST | 65% |
| “Revenue from new launches* (` in Million) ANDA dashboard Total 371 ANDAs(1) Investment in R&D (` in Million) `1,922 Mn FY 25 FY 24 FY 23 4.7% 4.3% 5.6% 1,922 1…” AR DOC | ||||||||
| CDSLCentral Depository Services (India) Ltd. | UNSTATED | — | — | — | — | FY26 | EST | 60% |
| “User ID for Shareholders holding shares in NSDL demat account is 8 Character DP ID followed by 8 Digit Client ID User ID for Shareholders holding shares in CDS…” AR · +1 DOC | ||||||||
| United States | UNSTATED | — | — | — | — | 2026-11 | EST | 50% |
| “Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to beco…” SCREENER DOC | ||||||||
| SUPPLIER | BASIS | EST ₹CR | RANGE | % COST | BUCKET | PERIOD | METHOD | CONF |
|---|---|---|---|---|---|---|---|---|
| BIOCONBiocon Ltd. | UNSTATED | — | — | — | — | FY25 | EST | 75% |
| “She serves as an Independent Director on the boards of Holcim SA, Gland Pharma Limited, Nayara Energy Limited and UPL Limited..” AR DOC | ||||||||
| UPLUPL Ltd. | UNSTATED | — | — | — | — | FY26 | EST | 75% |
| “She serves as an Independent Director on the boards of Nayara Energy Limited, Gland Pharma Limited, and Biocon Limited, and as a Non-Executive Director on the …” AR DOC | ||||||||
| SOURCE | READ | % | LAST READ |
|---|---|---|---|
| ANNUAL | 2/2 | 100% | 15-OCT-26 |
| CONCALL | 4/4 | 100% | 15-OCT-26 |
| SCREENER | 1/1 | 100% | 08-NOV-26 |
| SIGNAL | VALUE | AS OF | INPUTS |
|---|---|---|---|
| CUST MOM 1M | +12.4% | 15-NOV-26 | from 16-OCT-26 · Central Depository Services (India) Ltd. +12.4% |
| DISTRESS SCORE | 0.058 | 13-OCT-26 | roe 0.1 · operatingMargin 0.25 · debtToEquity 0.03 · interestCoverage 45.39 · assetTurnover 0.52 · leverage 1.2 |
| SUPP MOM 1M | +4.4% | 15-NOV-26 | from 16-OCT-26 · Biocon Ltd. +4.3% w 1 · UPL Ltd. +4.6% w 1 |
| TOP 10 CUSTOMERS % REV | 19.0% | 30-NOV-25 | sentence Our top 10 customers in the U.S. grown by around 19%, so yes, U.S is where we are growing. · documentId 1,138 |